NBP · I-Mab

NovaBridge’s 2025 financial results reflect a strategic pivot toward late-stage clinical development, marked by a $62.9M R&D spend increase — primarily driven by in-process R&D expenses tied to the VIS-101 acquisition through Visara and the Bridge Health bispecific/ADC asset acquisition. This investment aligns with the company’s stated transformation into a global biotech platform, evidenced by the expansion of its Board and executive team, including appointments of Dr. Robert Lenz as Chairman and Dr. Emmett T. Cunningham as Vice-Chairman. The $88.3M net loss from continuing operations is not indicative of operational deterioration but rather deliberate capital deployment: administrative expenses rose modestly ($1.7M), while interest income grew slightly on higher cash balances. Critically, the $210.8M cash position as of December 31, 2025 — explicitly projected to support operations through 2028 — provides substantial de-risking for upcoming milestones, including the potential YE 2026 initiation of givastomig’s registrational Phase 3 trial under FDA’s Accelerated Approval Pathway and VIS-101’s Phase 2b launch in H2 2026. Management commentary underscores confidence in clinical differentiation: givastomig’s 75% ORR and 16.9-month mPFS across broad CLDN18.2 expression levels, and VIS-101’s two-thirds four-month retreatment-free rate, both represent meaningful clinical validation. The allocation of $42.1M in losses to redeemable noncontrolling interests reflects Visara’s Series A liquidation preferences — a structural feature of the spoke model, not an ongoing cash outflow. Together, these facts signal a high-conviction, capital-efficient advancement of two near-commercial assets, with financials fully aligned to the disclosed 2026–2027 clinical roadmap.